RBC Capital reiterated an Outperform rating and $247 price target on Illumina (ILMN) after Roche (RHHBY) presented scientific details about its ...
Roche (RHHBY) unveiled its proprietary, breakthrough sequencing by expansion technology, establishing a new category of next-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback